1.22
2.52%
+0.03
After Hours:
1.22
AvroBio Inc stock is currently priced at $1.22, with a 24-hour trading volume of 398.89K.
It has seen a +2.52% increased in the last 24 hours and a -4.69% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.20 pivot point. If it approaches the $1.23 resistance level, significant changes may occur.
Previous Close:
$1.19
Open:
$1.21
24h Volume:
398.89K
Market Cap:
$54.75M
Revenue:
-
Net Income/Loss:
$12.16M
P/E Ratio:
-8.7143
EPS:
-0.14
Net Cash Flow:
$-63.20M
1W Performance:
+2.52%
1M Performance:
-4.69%
6M Performance:
-22.78%
1Y Performance:
+45.45%
AvroBio Inc Stock (AVRO) Company Profile
Name
AvroBio Inc
Sector
Industry
Phone
617 914 8420
Address
Building 300, Suite 201 One Kendall Square, Cambridge, MA
AvroBio Inc Stock (AVRO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-05-22 | Downgrade | BTIG Research | Buy → Neutral |
Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-15-21 | Initiated | BTIG Research | Buy |
May-27-21 | Initiated | Needham | Buy |
Mar-09-21 | Initiated | Barclays | Overweight |
Mar-02-21 | Initiated | Stifel | Hold |
Nov-11-20 | Initiated | Berenberg | Buy |
Mar-31-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jun-27-19 | Initiated | Mizuho | Buy |
Apr-05-19 | Initiated | Janney | Buy |
Oct-10-18 | Initiated | Guggenheim | Buy |
Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
Sep-17-18 | Initiated | H.C. Wainwright | Buy |
Jul-16-18 | Initiated | Morgan Stanley | Overweight |
Jul-16-18 | Initiated | Wedbush | Outperform |
Jul-16-18 | Initiated | Wells Fargo | Outperform |
View All
AvroBio Inc Stock (AVRO) Latest News
AvroBio Inc Stock (AVRO) Financials Data
AvroBio Inc (AVRO) Net Income 2024
AVRO net income (TTM) was $12.16 million for the quarter ending December 31, 2023, a +111.48% increase year-over-year.
AvroBio Inc (AVRO) Cash Flow 2024
AVRO recorded a free cash flow (TTM) of -$63.20 million for the quarter ending December 31, 2023, a +35.16% increase year-over-year.
AvroBio Inc (AVRO) Earnings per Share 2024
AVRO earnings per share (TTM) was $0.27 for the quarter ending December 31, 2023, a +111.20% growth year-over-year.
About AvroBio Inc
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):